ESPE Abstracts

Introduction: Somatropin has been the standard treatment for Growth hormone deficiency (GHD) since 1985. Nowadays, has been approved for the treatment of other diseases, as: Small for gestational age (SGA), Turner syndrome (TS) and Prader-Willi syndrome (PWS).

Aims: Assess the efficacy of somatropin in children followed in a tertiary Hospital, at 12 and 24 months of treatment, and to compare the results based on the patient’s disease. Methods: Fifty patients, who met the rigorous inclusion criteria and did not present any exclusion criteria, were divided in 4 groups based on their disease: isolated GHD (iGHD), SGA, TS and PWS. They were analysed in a retrospective, observational, descriptive and analytical study. Auxological and analytical parameters were collected at baseline, 12 months and 24 months of treatment. Descriptive and comparative statistics were performed.

Results: At baseline, the SGA group had the lowest height, weight and BMI SDS, and the iGHD group, the lowest corrected height, bone age and IGF-1 SDS. Only BMI SDS had a significantly difference in variation between groups, with a variation of -0.28±0.15 SDS (P=0.037) in the TS group, after 12 months. From baseline, iGHD and SGA groups improved significantly in weight, height, corrected height, bone age and IGF-1 SDS, either at 12 or 24 months. TS group improved significantly, from baseline, in height and corrected height SDS, at 12 and 24 months, and in IGF-1 and BMI SDS at 12 months. PWS group improvements didn’t reach significancy. There were not reported any major adverse effects during treatment.

Conclusions: The findings of this work allow us to conclude that somatropin is an effective and safe treatment, and can significantly increase height in iGHD, SGA and TS patients in the short term. However, despite having positive results for PWS patients, they failed to reach significance.